Hutchmed’s Phase III colorectal cancer trial meets primary endpoint
Fruquintinib’s safety profile in this trial was in line with priorly reported data from trials.
Japan
Latest in
Japan
Otsuka, Lundbeck report positive data from Phase III Alzheimer’s trial
The CMAI total score in brexpiprazole group was statistically higher than for those receiving placebo.
Daiichi Sankyo Phase III quizartinib trial reports positive AML data
Treatment with quizartinib plus chemotherapy offered a 22.4% decline in mortality risk versus standard chemotherapy alone.
AstraZeneca doses first subjects in Phase III lupus nephritis trial
The trial will assess the safety and efficacy of anifrolumab versus placebo in adults with active Class III or IV…
Shionogi’s Covid-19 antiviral offers quick virus clearance in Asian trials
In the Phase IIb trial of S-217622 that enrolled 428 patients in Japan and South Korea, no serious safety issues…
Fujifilm to halt enrolment in Phase III Covid-19 trial of Avigan in Japan
Fujifilm attributed the termination of new subject enrolment to the spread of the Omicron variant of the SARS-CoV-2 virus.
Daiichi Sankyo commences Phase I/II/III trial for Covid-19 booster in Japan
The trial will assess the safety and efficacy of the booster vaccine in healthy adult subjects in Japan.
Takeda’s Phase III CMV infection trial of Livtencity meets primary goal
In the trial, 55.7% of patients in the Livtencity arm attained CMV DNA level below the LLOQ by week eight.